View Press Releases
MetaboParis-Santé platform first in France to install Bruker In Vitro Diagnostic research by NMR* system at Université de Paris
PARIS, France: Université de Paris has installed new Bruker In Vitro Diagnostic research
(IVDr) nuclear magnetic resonance (NMR) spectrometer within its MetaboParis-Santé
platform located in the center of Paris city, France. One of the most prestigious universities
in France, known for its cutting-edge research in medicine and more broadly biology and
health, is the first facility in the country to benefit from a IVDr instrument of its kind.
MetaboParis-Santé is upheld as a national center of excellence for the metabolic analysis by
NMR of human biofluids.
Thanks to the Bruker IVDr technology, Université de Paris can now analyze human samples,
such as plasma, serum, or urine, to automatically obtain their composition and identify the
main metabolites present, more than one hundred parameters, all in less than 15 minutes.
The new IVDr system is an asset in supporting the diagnosis of conditions that present a
major public health issue: “Blood analyses will, for example, make it possible to make a
better assessment of cancer such as lymphoma by establishing a more detailed lipid profile
than that provided by conventional biological analysis methods,” explains Dr. Gildas Bertho,
Scientific Director of the MetaboParis-Santé platform. He continues: “Our work with
academic, industrial, and medical laboratories is what makes us so unique, and we
recognize the role of Bruker in supporting these collaborations.”
Claire Cannet, Market Manager for Clinical RTD at Bruker BioSpin: "Bruker is proud to
support the NMR community further and drive advanced research in the clinical research
field. The MetaboParis-Santé platform represents a huge step for innovative disease
analysis and, through its partnerships, together we are furthering knowledge into molecular
phenomics questions."
The MetaboParis-Santé project has established partnerships with Assistance Publique–
Hôpitaux de Paris (AP-HP) and other hospitals throughout France to use and promote NMR
technology, leading the way in research. It benefits from a national network of scientific
collaborations supported by the Île-de-France region, the French National Centre for
Scientific Research (CNRS) and the French National Institute of Health and Medical
Research (Inserm), and, at present, is engaged in two major national cohort studies in the
fight against cancer and COVID-19. Now that NMR has been established as a crucialtechnique within the MetaboParis-Santé project, it is the first step to revolutionize routine biological analysis in French laboratories.
About MetaboParis-Santé
MetaboParis-Santé is a metabolomic platform located in the NMR department (Dir G.
Bertho) of UMR8601 CNRS and administered by the UMS BioMedTech Facilities - Inserm
US36 | CNRS UMS2009 | Université de Paris. It deals with requests for biological analyzes
from the private and public sectors, mainly for metabolomics studies. This platform relies on
the spectroscopic expertise developed in the NMR of Biological Substances research team
(Dir N. Giraud) working with complex sample analysis strategies in the context of scientific
collaborations. This IVDr equipment, improved protocols, and the strong expertise of the
NMR staff in metabolomics brings together a large range of key players from academic,
industrial, and medical laboratories from hospitals. For more information, please visit:
About Université de Paris
Université de Paris is one of the leading research-intensive universities in France (4th in the
ARWU ranking, 1st in the Leiden ranking for the 1% of the most cited publications). Across a
broad range of disciplines that include health sciences, formal and experimental sciences
and the humanities and social sciences, Université de Paris builds on the highest quality
disciplinary research to cultivate multi and interdisciplinary collaborations in research and
education. Université de Paris is composed of three Faculties (Health, Sciences and
Humanities and Social sciences), a component institution, the Paris Institute of Earth
Physics, (IPGP) and now a partner research organization, the Institut Pasteur. Université de
Paris has 63,000 students, 7,500 teacher-researchers and researchers, 21 doctoral schools
and 119 research units.
About Bruker Corporation
Bruker is enabling scientists to make breakthrough discoveries and develop new
applications that improve the quality of human life. Bruker’s high performance scientific
instruments and high value analytical and diagnostic solutions enable scientists to explore
life and materials at molecular, cellular, and microscopic levels. In close cooperation with our
customers, Bruker is enabling innovation, improved productivity, and customer success in
life science molecular and cell biology research, in applied and pharma applications, in
microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinica limaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.
* Bruker NMR is for Research Use Only and not for use in Clinical Diagnostic Procedures Customer
Contact: Media Contact (Bruker):
Thorsten Thiel
VP of Group Marketing
Bruker BioSpin Group
thorsten.thiel@bruker.com
Claire Cannet
Bruker BioSpin Group
Market Manager Clinical RTD
claire.cannet@bruker.com